Src homology 2 (SH2) domains are composed of weakly conserved sequences of ∼100 aa that bind phosphotyrosines in signaling proteins and thereby mediate intra-and intermolecular protein-protein interactions. In exploring the mechanism whereby tyrosine phosphorylation of the erythrocyte anion transporter, band 3, triggers membrane destabilization, vesiculation, and fragmentation, we discovered a SH2 signature motif positioned between membrane-spanning helices 4 and 5. Evidence that this exposed cytoplasmic sequence contributes to a functional SH2-like domain is provided by observations that: (i) it contains the most conserved sequence of SH2 domains, GSFLVR; (ii) it binds the tyrosine phosphorylated cytoplasmic domain of band 3 (cdb3-PO 4 ) with K d = 14 nM; (iii) binding of cdb3-PO 4 to erythrocyte membranes is inhibited both by antibodies against the SH2 signature sequence and dephosphorylation of cdb3-PO 4 ; (iv) label transfer experiments demonstrate the covalent transfer of photoactivatable biotin from isolated cdb3-PO 4 (but not cdb3) to band 3 in erythrocyte membranes; and (v) phosphorylation-induced binding of cdb3-PO 4 to the membrane-spanning domain of band 3 in intact cells causes global changes in membrane properties, including (i) displacement of a glycolytic enzyme complex from the membrane, (ii) inhibition of anion transport, and (iii) rupture of the band 3-ankyrin bridge connecting the spectrin-based cytoskeleton to the membrane. Because SH2-like motifs are not retrieved by normal homology searches for SH2 domains, but can be found in many tyrosine kinase-regulated transport proteins using modified search programs, we suggest that related cases of membrane transport proteins containing similar motifs are widespread in nature where they participate in regulation of cell properties.
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SH2 domain motif | tyrosine phosphorylation | erythrocyte glycolysis | anion exchanger 1 | regulation of transport proteins P rotein tyrosine phosphorylation is involved in the regulation of most cellular process, including proliferation, survival, differentiation, responses to stress, and control of cell shape/motility (1) . Whereas phosphotyrosine binding (PTB) domains may mediate association with tyrosine-containing sequences regardless of their phosphorylation state, Src homology 2 (SH2) domains promote protein association only when critical tyrosine residues become phosphorylated. This strict dependence on tyrosine phosphorylation creates a molecular switch that can be sensitively controlled by upstream tyrosine kinases (1) . Whereas some SH2 domains facilitate association between heterologous proteins in a signaling pathway, others mediate intrapolypeptide interactions that change protein conformation and thereby alter signaling function (2) . In all cases, association between the SH2 domain and the interacting phosphotyrosine involves formation of weak interactions between a highly conserved G(S/T)FLVR sequence of the SH2 domain and the phosphate present on the phosphorylated tyrosine. To date, all 120 known SH2 domains in the human genome are composed of moderately conserved sequences of ∼100 contiguous aa (3) , and no functional SH2 domain has been reported that contains only the critically conserved residues interrupted by unrelated sequences.
Band 3 (the erythrocyte anion exchanger, AE1, or SLC4A1) constitutes the most abundant polypeptide in the erythrocyte membrane (∼1.2 × 10 6 copies per cell) where it serves as a major center of membrane organization (4) . The cytoplasmic domain of band 3 (cdb3) binds and organizes at least 13 different peripheral proteins on the membrane, whereas the membrane-spanning domain catalyzes anion transport and binds a different constellation of membrane proteins. Proteins believed to interact directly with band 3 include most glycolytic enzymes, multiple kinases, two phosphatases, protein 4.1, protein 4.2, adducin, ankyrin, carbonic anhydrase, hemoglobin, peroxiredoxin, Rh polypeptide, CD47, and glycophorins A and B (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . As anticipated, physiological modulations of band 3 regulate processes involving these proteins, including glucose metabolism, membrane mechanical stability, cell morphology, intracellular redox balance, cytoplasmic pH, and anion and cation transport across the membrane (15) (16) (17) (18) (19) (20) . Included among the stimuli that regulate band 3 functions is the phosphorylation of band 3 on tyrosines 8, 21, 359, and 904 (21, 22) . These phosphorylation events control the partitioning of glucose metabolism between glycolysis and the pentose phosphate pathway (15) , regulate the linkage between band 3 and the spectrin-based cytoskeleton, and modulate cell morphology/stability (22) . In our search for a mechanism to explain these multifarious effects, we discovered a highly conserved SH2 domain signature sequence in band 3, positioned in a cytoplasmic loop between two membrane-spanning helices. The experiments described below document the functionality of this remarkable SH2-like domain, summarizing its properties and describing the structural consequences of its docking with the tyrosine phosphorylated residues in the cytoplasmic domain of band 3.
Results
Tyrosine Phosphorylation of Intact Band 3 but Not the Isolated Cytoplasmic Domain of Band 3 Reduces Its Binding Affinity for Ankyrin.
Our motivation to search for a possible SH2-like domain in band 3 arose from two apparently contradictory observations. First, ankyrin
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Src homology 2 (SH2) domains regulate signaling by binding phosphotyrosines. While all known SH2 domains consist of contiguous sequences of ∼100 aa, we describe a highly conserved SH2-like sequence motif located in the second cytoplasmic loop of membrane-spanning domain of erythrocyte membrane band 3. Upon tyrosine phosphorylation of the cytoplasmic domain of band 3, the domain rotates to bind the SH2 signature sequence within the membrane-spanning domain of band 3, promoting significant changes in erythrocyte properties. Because sequence homology searches do not recognize SH2-like sequence motifs, the possibility arises that many other SH2-like structures remain undetected in membrane-spanning proteins where they perform critical steps in kinase-facilitated signaling pathways.
binding to the cytoplasmic domain of band 3 (cdb3) in potassium iodide (KI)-stripped inside-out erythrocyte membrane vesicles (KIIOVs) was found to be partially inhibited by tyrosine phosphorylation of band 3, whereas binding of ankyrin to the isolated dimeric cdb3 was not. Thus, as shown in Fig. 1 (Fig. 1B) ; i.e., demonstrating that o-vanadate induced tyrosine phosphorylation of band 3 reduces ankyrin affinity for KI-IOVs. Evidence that this decrease in ankyrin affinity indeed derives from tyrosine phosphorylation of band 3 is provided both by blots showing that the loss of ankyrin affinity correlates with the phosphorylation of band 3 ( Fig. 1A) and that the phosphorylation-induced decrease in ankyrin affinity is reversed upon removal of the tyrosine phosphates by phosphatases (K d ∼85 nM; Fig. 1 A and B) . Importantly, these data are congruent with previously published observations demonstrating that phosphorylation of Y8 and Y21 of band 3 by spleen tyrosine kinase (SYK) blocks ankyrin binding to band 3, both in intact RBCs and in KI-IOVs (22) . The aforementioned conflicting observation arose when the phosphorylation-induced inhibition of ankyrin binding to band 3 was examined using the purified cdb3 (i.e., the domain to which ankyrin binds) (6) rather than intact band 3 in KI-IOVs. Thus, as shown in Fig. 1C , tyrosine phosphorylation of purified cdb3 by recombinant SYK kinase (i.e., the major tyrosine kinase that phosphorylates band 3 in vivo) (14) has no impact on the binding of D3D4-ankyrin (23) to cdb3, as demonstrated by the similar ability of phosphorylated and nonphosphorylated cdb3 to copellet D3D4-ankyrin in standard pulldown assays.
Discovery of a Functional SH2-Like Sequence in Band 3. To determine why tyrosine phosphorylation might inhibit band 3-ankyrin interactions in both whole RBCs and KI-IOVs, but not when purified phospho-cdb3 (cdb3-PO 4 ) was used as the binding partner, we searched for an SH2 domain on the erythrocyte membrane that might bind cdb3-PO 4 in situ but be absent in a binding assay containing only purified cdb3. The signature sequence for which we screened was GSFLVR, because this sequence is the most highly conserved among all 120 known human SH2 domains (24) and is shown to be essential for phosphotyrosine binding (24, 25) . Importantly, the only KI-IOV protein retrieved in the homology search was band 3 ( Fig. 2A and Fig. S1 ), and the highly conserved 509-GSFLVR-514 peptide was surprisingly found in an exposed region of the cytoplasmic loop connecting membrane-spanning helices 4 and 5 ( Fig. S2) (26, 27) . Moreover, the weakly conserved sequences flanking GSFLVR in classical SH2 domains were absent from the sequences flanking 509-GSFLVR-514 in band 3. Although the probability that the GSFLVR sequence could have evolved by chance is only 1 in 20 6 (i.e., there are six residues and each has a random chance of 1/20 of being the conserved amino acid), the absence of the expected flanking sequences in a classical SH2 domain mandated that we demonstrate the functionality of this hypothesized SH2-like domain by standard methods.
To explore the functional properties of the putative SH2 domain signature sequence, we prepared stripped and trypsin-digested insideout erythrocyte membrane vesicles (SD-IOVs) that lack all peripheral proteins as well as the cdb3, but still contain a functional membrane-spanning domain of band 3. As shown in Fig. 2B , addition of increasing concentrations of unmodified cdb3 to these SD-IOVs showed a low affinity interaction with an apparent K d of ∼170 nM. In contrast, titration of SYK-phosphorylated cdb3 (cdb3-PO 4 ) into the same SD-IOVs produced an analogous binding isotherm with an apparent K d of ∼14 nM. Because dephosphorylation of cdb3-PO 4 by treatment with the tyrosine phosphatase PTP1B reduced the high-affinity interaction to the same level seen with nonphosphorylated cdb3 (i.e., K d ∼155 nM), we conclude that the high-affinity association of cdb3-PO 4 requires tyrosine phosphorylation of band 3. Importantly, similar results were also obtained using a pull-down assay ( Fig. 2 C and D) , confirming that the high-affinity binding of cdb3 to SD-IOVs requires the SYKmediated tyrosine phosphorylation of band 3.
To further establish the presence of a functional SH2-like sequence in band 3, we next prepared an antibody against the cytoplasmic loop in the membrane-spanning domain of band 3 containing the GSFLVR signature sequence (507-FEGSFLVR-FISRYTQE-522) and examined its ability to block association of cdb3-PO 4 with SD-IOVs. As seen in Fig. 3A , the prominent polypeptide recognized by this anti-SH2 peptide antiserum in erythrocyte membranes is band 3 (lane 2), as demonstrated by the staining of the same polypeptide with a monoclonal antibody to band 3 (lane 3). However, because two additional proteins were also recognized by the anti-SH2 peptide antiserum, it was essential that we include the preimmune serum that recognizes the same two additional proteins as a control in the studies using the anti-SH2 signature sequence antiserum. Importantly, preincubation of the anti-SH2 signature sequence antiserum with SD-IOVs was found to reduce cdb3-PO 4 binding to a level similar to nonphosphorylated cdb3 (Fig. 3B ), whereas preincubation with the preimmune serum from the same rabbit caused no decrease in cdb3-PO 4 binding. These data also support the hypothesis that the high-affinity cdb3-PO 4 binding site on SD-IOVs resides in the discontinuous SH2 domain of band 3. To further confirm the interaction of cdb3-PO 4 with the SH2 domain signature motif of band 3, we labeled cdb3-PO 4 with the biotinylated photocross-linking reagent, sulfo-SBED (Thermo Scientific Pierce) and examined whether its photoactivation in the presence of SD-IOVs might mediate phototransfer of biotin from cdb3-PO 4 to the membrane-spanning domain of band 3. After washing the SD-IOVs to remove unbound cdb3-PO 4 and then illuminating to catalyze photocross-linking, the disulfide bridge in sulfo-SBED connecting cdb3-PO 4 to its unknown binding partner on the membrane was reduced and the identity of this biotinylated partner on the membrane was determined by Western blotting. As seen in Fig. 3C , the predominant biotinylated partner (lane 1 in streptavidin-HRP) was band 3, as confirmed by subsequent staining with antiband 3 monoclonal antibody. To more conclusively establish these results, parallel experiments were performed in which the SH2 domain was blocked with either anti-SH2 signature sequence antibody (Fig. 3C, lane 2) or an ∼10-fold excess of unlabeled cdb3-PO 4 (Fig.  3C, lane 3) before incubation with sulfo-SBED-labeled cdb3-PO 4 . As shown in lanes 2 and 3, both the anti-SH2 signature sequence antiserum and excess cdb3-PO 4 successfully competed for cdb3-PO 4 cross-linking to SD-IOVs, i.e., confirming that cdb3-PO 4 is indeed selectively binding to the SH2 domain signature motif in band 3 and not some other erythrocyte membrane protein. Based on all of these results, we conclude that tyrosine phosphorylation of cdb3 promotes its association with an SH2-like domain within the membranespanning domain of band 3.
Impact of cdb3-PO 4 Binding to the SH2 Domain Signature Motif of Band 3 on Erythrocyte Properties. To explore whether engagement of the SH2-like motif by phosphorylated cdb3 might impact important properties of the human erythrocyte, we induced tyrosine phosphorylation in intact erythrocytes and examined its impact on erythrocyte biology. As shown in Fig. 4A , lane 1, addition of pervanadate to whole erythrocytes results in prominent tyrosine phosphorylation of band 3. Because this phosphorylation can be quantitatively prevented by pretreatment with SYK kinase inhibitors (SYK inh.II, PRT06607, R406, and imatinib; Fig. 4A, lanes 2-5) , we conclude that the major tyrosine kinase responsible for the pervanadate-induced phosphorylation of band 3 is likely SYK, although the fact that each of the above inhibitors undoubtedly has off-target activities against other tyrosine kinases precludes any conclusion that SYK must be the only kinase involved. Examination of the morphology of the pervanadate-treated red cells confirms that the predicted membrane destabilization associated with rupture of the band 3-ankyrin interaction is observed, as evidenced by the prominent membrane crenation, blebbing, and sphering of the treated cells (Fig. 4B) .
Because a fraction of pervanadate-treated erythrocytes always resists morphological change, we next explored whether the resistant fraction might be characterized by reduced tyrosine phosphorylation. As seen in the antiphosphotyrosine-stained cells of Fig. 4C , only erythrocytes that are tyrosine phosphorylated (green stain) exhibit abnormal morphologies, confirming the causal relationship between tyrosine phosphorylation of band 3 and membrane destabilization. Moreover, because blockade of this tyrosine phosphorylation by a SYK inhibitor prevents these morphological changes (Fig. 4C, pervanadate column) , we conclude that SYK-mediated tyrosine phosphorylation of band 3 is linked to the observed membrane destabilization.
To pursue the relevance of SH2-like motif engagement to still other erythrocyte properties, we next examined whether the organization of the well-characterized glycolytic enzyme complex on band 3 (28) might be regulated by tyrosine phosphorylation of band 3. As seen by displacement of GAPDH (Fig. 4C ) and other glycolytic enzymes (Fig. S3 ) from the membranes of only tyrosine phosphorylated cells, the SH2-like motif-mediated conformational change in band 3 can be concluded to also impact the organization of this glycolytic enzyme complex on band 3.
Because another major function of band 3 involves its catalysis of Cl − for HCO 3 − exchange across the membrane (i.e., a process required for transport of CO 2 as HCO 3 − from the tissues to the lungs), we next examined the effect of tyrosine phosphorylation on anion exchange through band 3. As shown in Fig. 4D , tyrosine phosphorylation of band 3 (promoted by resealing of SYK kinase plus ATP into lysed erythrocytes) causes complete inhibition of anion transport (i.e., the level of anion exchange across the resealed erythrocyte membrane is reduced to a level seen in DIDS-inhibited samples) (29) . Moreover, prevention of the tyrosine phosphorylation by preaddition of SYK kinase inhibitors prevents this blockade of anion transport. Furthermore, resealing of the anti-SH2 domain antibody (but not the preimmune serum) into the lysed red cells eliminates the kinase-mediated inhibition of anion transport. Taken together, these data suggest that the phosphorylation-induced engagement of the SH2 domain signature sequence in band 3 with cdb3-PO 4 also induces changes in anion transport.
Based on all of the above studies, we wish to propose a mechanism to explain the phosphorylation-stimulated changes in erythrocyte membrane properties. Upon administration of pervanadate (a potent tyrosine phosphatase inhibitor), the constitutive equilibrium in tyrosine phosphorylation of band 3 shifts strongly toward the phosphorylated state; i.e., tyrosines 8, 21, 359, and 904 in band 3 all become phosphorylated (30) . As cartooned in Fig. 4E , this phosphorylation promotes the interaction of cdb3-PO 4 (and perhaps phosphotyrosine 904 at the cytoplasmically exposed COOH terminus in the membrane-spanning domain of band 3) with the SH2-like motif in the membrane-spanning domain of band 3, inducing a global conformational change in the anion transporter that causes release of glycolytic enzymes (21), displacement of ankyrin from cdb3 (22) , and inhibition of anion transport. Whereas dissociation of both the glycolytic enzymes and ankyrin from cdb3 can be explained as logical consequences of the induced reorientation/ conformation of cdb3, the inhibition of anion transport may be more complex. Thus, the amino acid sequence that encompasses the SH2 signature motif specifically forms the bridge that precisely spans between the two halves of the membrane-spanning domain of band 3. Because these two halves of band 3 must pivot back and forth to catalyze anion transport (26, 27) , binding of cdb3-PO4 solely to one of the two conformations would be expected to lock the anion transporter in that conformation and thereby inhibit anion transport.
Based on analysis of the crystal structure of band 3 (26, 27) , the GSFLVR bridging peptide can be seen to exist in an α-helical conformation when the transport site faces outwards, but must extend to an elongated conformation when the transport site opens up to the cytoplasm. Given that the GSFLVR sequence in SH2 domains exists in an elongated conformation, one would predict that cdb3-PO 4 (or phosphorylated Y904) might only bind to the inward facing conformation of band 3.
Discussion
We report the existence of a functional SH2-like motif that resides in a cytoplasmic loop between consecutive helices of a membranespanning protein. We further show that docking of this SH2 signature sequence with the tyrosine phosphorylated cdb3 induces major changes in the structure and function of the whole membrane, including dissociation of a glycolytic enzyme complex from the membrane, displacement of ankyrin (i.e., the major bridge connecting the membrane to the spectrin-based cytoskeleton) from band 3, and inhibition of anion transport through band 3. Release of the glycolytic enzyme complex from the membrane has been previously shown to shift the catabolism of glucose from the pentose phosphate pathway to glycolysis (15) , whereas disjunction of ankyrin from band 3 has been found to significantly destabilize the membrane (22) . Inhibition of anion transport not only suppresses transport of CO 2 as HCO 3 − from the tissues to the lungs, but also affects intracellular pH and the volume of the red cells (20) . Whether other red cell properties are similarly modulated by tyrosine phosphorylation of band 3 will require further scrutiny, but the fact that the cdb3 is known to interact with at least 13 other proteins should render this conjecture highly likely.
Although the SH2 docking mechanism can account for the data presented here, it must also be recognized that the proposed mechanism is not unique in its ability to explain our observations. First, whereas we have focused on the interaction between cdb3-PO 4 and the SH2 sequence motif, it is also plausible that phosphorylated Y904 at the COOH terminus of band 3 could similarly dock with the SH2 sequence motif. Thus, Y904 resides in a cytoplasmically exposed, unstructured peptide (i.e., the COOH-terminal residues 883-911 are not resolved in the crystal structure) whose sequence (DEYDE) is similar to the peptide containing Y8 (DDYED) and Y21 (EEYED). Importantly, if phosphorylated Y904 were to bind the SH2 motif, the biological consequences would likely be limited to inhibition of anion transport, because the conformation/orientation of cdb3 would remain unaltered. In this scenario, a kinase that phosphorylated solely Y904 could regulate anion transport without altering glycolysis or membrane stability. Second, because band 3 exists in an equilibrium between dimers and tetramers (31), it remains possible that a cdb3-PO 4 from one subunit could dock with the SH2-like motif of an adjacent subunit, thus communicating the phosphorylation status of band 3 between subunits in an oligomer or even promoting association of band 3 monomers to higher oligomers. Third, band 3 may not constitute the sole protein that is tyrosine phosphorylated upon pervanadate treatment, allowing the possibility that less prominent tyrosine phosphorylated proteins might participate in this regulatory process. Indeed, we have observed that tyrosine phosphorylated SYK kinase can also bind to band 3. Finally, although all of our studies have presumed a predominant role for SYK kinase in phosphorylating band 3, there is abundant evidence that other erythrocyte tyrosine kinases (i.e., Lyn, Fgr, Src, Hck, insulin receptor) can phosphorylate at least one of the commonly phosphorylated tyrosines in band 3 (i.e., tyrosines 8, 21, 359, and 904). It will be interesting in the future to determine which changes in RBC biology these kinases can induce.
Whereas the function of this regulatory pathway in healthy cells remains uncertain, it should be noted that dramatically more tyrosine phosphorylation of band 3 is seen in pathologies such as sickle cell disease and β-thalassemia (32), G6PD deficiency (33), sepsis (34) , and malaria parasitemia (35) . Not surprisingly, most of these diseases are also characterized by an abnormal erythrocyte membrane stability/morphology, an altered rate of erythrocyte glucose metabolism, and aberrant ion transport properties (36) (37) (38) (39) (40) , raising the question of whether tyrosine phosphorylation of band 3 might also contribute to the development of these diseases. Indeed, the membrane blebbing and vesiculation seen in most of the above pathologies are now thought to contribute prominently to the vasoocclusive/thrombotic events that plague many of these patients (41) , opening the question of whether a SYK kinase inhibitor might constitute a method for treating these diseases. Although a mechanistic linkage between enhanced band 3 tyrosine phosphorylation and the etiologies of the above diseases has never been explored, it is interesting to note that sickle cell disease has been unintentionally treated with imatinib, a breakpoint cluster region-Abelson (bcr-abl) tyrosine kinase inhibitor that has off-target activity against SYK (Fig. 4A and ref. 42) . Thus, administration of imatinib to patients with chronic myelogenous leukemia who also have sickle cell disease has been fortuitously found to suppress all major symptoms of the disease (43) (44) (45) . Whereas a role for phosphorylation-triggered changes in several RBC pathologies may be plausible, the purpose for which the pathway originally evolved seems less certain. Thus, as noted with the aforementioned pathological cells, aging RBCs suffer an inability to maintain their cytosols in a reducing state. As a consequence, glutathione levels drop precipitously at the end of an erythrocyte's lifespan (46) , methemoglobin is no longer reduced to hemoglobin but instead forms hemichromes, band 3 becomes tyrosine phosphorylated and is released from its attachment to the cytoskeleton (22) , the anion transporter aggregates into clusters that bind autologous antibodies (47) , and the antibody-coated erythrocytes are removed by Fc receptor expressing phagocytes in the liver and spleen (48) . Because this senescent RBC clearance pathway is facilitated by the tyrosine phosphorylation of band 3, it is conceivable that at least one beneficial function of the phosphorylation pathway might involve the apoptosis and subsequent removal of senescent erythrocytes.
With the evidence for a functional SH2-like motif in the membrane-spanning domain of band 3 now established, and with considerable data showing that many other membrane-spanning solute transporters are also regulated by tyrosine kinases (49, 50) , the question naturally arose of whether other membrane-spanning proteins might have evolved a similar functional SH2 signature sequence to enable their regulation by tyrosine kinases. Examination of the literature reveals that sequences similar to GSFLVR can indeed be found in numerous transport proteins, ranging from neurotransmitter symporters to glucose transporters to cation-Cl − electroneutral cotransporters, etc. (Fig. S4) . Because many of these transporters are also regulated by tyrosine phosphorylation (49, 50) , and because their malfunction can contribute to human disease, it will be important in the future to determine whether their structures contain a functional SH2-like motif similar to that discovered here and whether their mechanism of regulation resembles that depicted in Fig. 4E .
Materials and Methods
GST-D3D4-Ankyrin Binding Assay to Control, Phosphorylated, or Dephosphorylated KI-IOVs. KI-IOV preparation of untreated or orthovanadate-treated erythrocytes was done following refs. 6 and 51 in the absence (dephosphorylated) or presence of phosphatase inhibitors (phosphorylated). Binding of increasing concentrations of GST-D3D4-ankyrin to KI-IOV was carried out as described previously (22) with a few modifications described in SI Materials and Methods.
